4D Molecular Therapeutics, Inc. (FDMT) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 92.01M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $92.01M | (m) | (m) |
| 2026-03-31 | (m) | $88.24M | (m) | (m) |
| 2025-12-31 | (m) | $85.21M | (m) | (m) |
| 2025-09-30 | (m) | $120.00K | (m) | (m) |
| 2025-06-30 | (m) | $33.00K | (m) | (m) |
| 2025-03-31 | (m) | $23.00K | (m) | (m) |
| 2024-12-31 | (m) | $37.00K | (m) | (m) |
| 2024-09-30 | (m) | $17.00K | (m) | (m) |
| 2024-06-30 | (m) | $20.22M | (m) | (m) |
| 2024-03-31 | (m) | $20.45M | (m) | (m) |
| 2023-12-31 | (m) | $20.72M | (m) | (m) |
| 2023-09-30 | (m) | $21.99M | (m) | (m) |
| 2023-06-30 | (m) | $2.29M | (m) | (m) |
| 2023-03-31 | (m) | $2.21M | (m) | (m) |
| 2022-12-31 | (m) | $3.13M | (m) | (m) |
| 2022-09-30 | (m) | $1.97M | (m) | (m) |
| 2022-06-30 | (m) | $2.84M | (m) | (m) |
| 2022-03-31 | (m) | $17.26M | (m) | (m) |
| 2021-12-31 | (m) | $18.04M | (m) | (m) |
| 2021-09-30 | (m) | $16.97M | (m) | (m) |
| 2021-06-30 | (m) | $23.02M | (m) | (m) |
| 2021-03-31 | (m) | $11.95M | (m) | (m) |
| 2020-12-31 | (m) | $13.36M | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $6.96M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |